AP
ANIK icon

Advisors Preferred’s Anika Therapeutics ANIK Stock Holding History

Advisors Preferred’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-536
Closed -$24.8K – 214
2014
Q2 		$24.8K Buy
+536
New +$23.8K 0.01% 227
2014
Q1 		– Sell
-804
Closed -$30K – 339
2013
Q4 		$30K Buy
+804
New +$24.8K 0.02% 214

Other funds holding ANIK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GAM
Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return

Advisors Preferred's ANIK Position: Q3 2014 in Review

Advisors Preferred sold out of Anika Therapeutics (ANIK) in Q3 2014, closing a stake of 536 shares — an estimated $24.8K sold.

Advisors Preferred first reported a position in ANIK in Q4 2013 and held it in 2 quarters. The position peaked at $30K in Q4 2013. 153 funds tracked by Wall St. Rank hold ANIK as of Q3 2014.

  • Advisors Preferred reported no remaining Anika Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Advisors Preferred sold 536 Anika Therapeutics shares in Q3 2014, an estimated $24.8K.
  • Advisors Preferred first reported a position in Anika Therapeutics in Q4 2013 and held it in 2 quarters.
  • Advisors Preferred's Anika Therapeutics position peaked at $30K in Q4 2013.
  • 153 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2014.

Based on Advisors Preferred's 13F filing for Q3 2014, filed 12 Nov 2014.